Safety and long-term efficacy of fractional CO 2 laser treatment in women suffering from genitourinary syndrome of menopause

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:39-44. doi: 10.1016/j.ejogrb.2017.03.036. Epub 2017 Apr 2.

Abstract

Objectives: To evaluate the safety and long-term efficacy of fractional CO2 laser treatment in reducing the severity of symptoms of genitourinary syndrome of menopause (GSM) in menopausal women.

Study design: 102 women presenting with symptomatic GSM were treated with the fractional CO2 laser (MonaLisa Touch, DEKA) system across a series of treatments delivered at intervals of six or more weeks. The Australian Pelvic Floor Questionnaire was used to gather data on sexual function and side-effects at three time-points across the study period (prospective panel design study). Wilcoxon signed-rank tests were used to detect statistically and clinically significant changes in sexual function and side-effects occurring from pre- to post-treatment. The primary outcome of this study was an improvement of the symptoms of GSM. The secondary outcome included bladder function and prolapse symptoms.

Results: A total of 102 women suffering from moderate to severe GSM were recruited. Eighty-four percent experienced significant improvement in their symptoms after CO2 laser treatment. Scores on measures of sexual function, dyspareunia, and bothersomeness of sexual issues were improved from pre-treatment to long-term (12-24 month) follow-up. Furthermore, there were improvements on measures of bladder function (P=0.001), prolapse (P=0.001), vaginal sensation (P=0.001), vaginal lubrication (P<0.001) and urge incontinence (P=0.003) from the pre-treatment assessment to the second assessment (i.e. after the third treatment).

Conclusions: In this study, fractional microablative CO2 laser treatment was associated with an improvement in symptoms of GSM and sexual function.

Keywords: Bladder control; Fractional CO(2) laser; Genitourinary syndrome of menopause; Menopause; Sexual function.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Australia / epidemiology
  • Dyspareunia / epidemiology
  • Dyspareunia / therapy
  • Female
  • Female Urogenital Diseases / complications
  • Female Urogenital Diseases / physiopathology
  • Female Urogenital Diseases / surgery*
  • Humans
  • Laser Therapy / adverse effects
  • Laser Therapy / methods*
  • Lasers, Gas*
  • Menopause / physiology*
  • Middle Aged
  • Postmenopause / physiology
  • Prospective Studies
  • Sexual Dysfunction, Physiological / epidemiology
  • Sexual Dysfunction, Physiological / therapy
  • Syndrome